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Type IA endoleaks associated with endovascular aortic aneurysm repair are typically treated with endovascular adjuncts.
Technical failure results when such maneuvers are unsuccessful, and endograft removal may, unfortunately, become
necessary. The novel management of a recalcitrant type IA endoleak using the artificial embolization device, Onyx (Micro
Therapeutics Inc, Irvine, Calif) is presented for the case of a nonagenarian with prohibitive surgical risk after conventional
techniques had failed. (J Vasc Surg 2010;52:1346-9.)Abdominal aortic aneurysm (AAA) rupture results in
15,000 deaths annually in the United States.1 In 1991,
Parodi2 popularized endovascular aortic aneurysm repair
(EVAR), and since then, EVAR has proven to be a major
technical advancement, albeit an imperfect one. Endoleaks
remain the Achilles’ heel of the modern endograft since the
authoritative description by White et al.3,4
The rate of secondary interventions after EVAR ranges
from 10% to 18%. These interventions are often necessary to
maintain successful AAA exclusion.5-8 Type IA endoleaks,
with a reported incidence as high as 10%, are among the
leading factors that necessitate secondary interventions.9
When detected, type IA endoleaks must be eliminated be-
cause they are associated with persistent pressurization of the
aneurysmal sac and risk of aneurysm rupture. The sealing of a
proximal endoleak has traditionally been accomplished by
endovascular means, with deployment of a Palmaz stent or a
proximal extension cuff.10 Conversion to open repair is usu-
ally reserved for cases of endovascular failure. This report
details the management of a nonagenarian at prohibitive op-
erative risk in whom traditional endovascular techniques
failed. To the best of our knowledge, this is the first reported
case to describe the successful management of a recalcitrant
type IA endoleak using ethylene vinyl alcohol copolymer
dissolved in dimethyl sulfoxide (EVOH/DMSO) and sus-
pended micronized tantalum powder (Onyx; Micro Thera-
peutics Inc, Irvine, Calif).
CASE REPORT
A 92-year-old woman presented with a complaint of new
abdominal pain. The physical finding of a tender and pulsatile
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1346abdominal mass led to the clinical diagnosis of a symptomatic AAA.
Because her hemodynamic indicators were stable, computed to-
mography (CT) imaging was obtained to determine if the patient
was a candidate for EVAR.
The proximal seal zone of this 6.5-cm infrarenal AAA was not
ideal for EVAR. The neck diameter measured 21.5 mm on the first
CT image below the most inferior renal artery, and the neck length
was determined to be 6 mm using the method described by Green-
berg.11 Reverse taper configuration was present, with a 41.7% increase
in diameter (30.5 mm) over the first 15 mm of infrarenal aorta.
However, open AAA repair was felt to be an option of prohibitive risk.
Given the urgency of this problem, endovascular repair was
offered and promptly commenced. The Zenith (Cook, Blooming-
ton, Ind) bifurcated modular device (32-  103-mm main body)
with suprarenal fixation and two docking limbs was used. A com-
pletion angiogram demonstrated a type IA endoleak that was
eliminated with a Palmaz XL P-4010 stent (Cordis, Warren, NJ)
mounted on a Z-MED-X 28-  40-mm noncompliant balloon
(NuMED, Hopkinton, NY). The patient’s recovery was unevent-
ful, and she was discharged to home.
The follow-up assessment at 1 year demonstrated aneurysm
sac shrinkage from 6.5 cm to 5.3 cm (Fig 1) and absence of any
endoleak. The patient returned 2 years after the original procedure
with recurrent abdominal pain. CT imaging demonstrated aneu-
rysm sac expansion from 5.3 to 6 cm and the presence of an
apparent type IA endoleak that was subsequently confirmed with
angiography to originate from the right aspect of the neck. Interval
growth in the neck diameter from 21.5 to 26.9 mm was observed
and felt to be responsible. There was no evidence of distal device
migration with respect to the left (lower) renal artery; however, the
neck dilation resulted in a conformational change that made it
possible to cover more neck on the right side that would have
previously resulted in coverage of the left renal artery. Attempts at
sealing the endoleak using a 32-  58-mm aortic extension cuff
and a second Palmaz stent were unsuccessful.
The patient declined the high-risk option of open surgical
repair in favor of a final endovascular attempt at aneurysm exclu-
sion. Here the endoleak channel was engaged endoluminally from
groin access with a SOS Omni (AngioDynamics, Queensbury, NY)
selective catheter, and an Echelon (ev3 Endovascular, Plymouth,
Minn) catheter was advanced coaxially under fluoroscopic visual-
ization into the aneurysm sac over a 0.014-inch Transend wire
(Boston Scientific, Natick, Mass). To safely deliver the Onyx at the
meter
dolea
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of the Palmaz stent to provide a stable platform for the Echelon
catheter and avoid direct contact with the agent.
The aneurysm sac was embolized using the artificial emboli-
zation device, Onyx (Micro Therapeutics Inc, Irvine, Calif). Ini-
tially, two vials of Onyx 18 were used because its lower viscosity
permits superior penetration into the aortic sac. To minimize the
risk of reflux into the aorta as the endoleak channel filled, the
Fig 1. Decrease in aneurysm sac dia
Fig 2. A, Endoleak at time of initial endovascular aneur
C, Neck degeneration resulting in type IA endoleak 1 y
identifies SOS guiding catheter buttressed against the in
direct contact with Onyx. E, Resolution of a type IA enembolization agent was switched to Onyx 34, which has greaterviscosity, and required four vials. Completion angiogram demon-
strated successful aneurysm exclusion (Fig 2). The patient has been
free of abdominal pain and without radiographic evidence of type
IA endoleak or aneurysm sac expansion for 1 year.
DISCUSSION
Aneurysm rupture after EVAR is a devastating compli-
after endovascular aneurysm repair.
epair (EVAR). B, Palmaz stent eliminated the endoleak.
fter EVAR. D, Delivery of Onyx into nidus. The arrow
ices of Palmaz stent, providing support and a barrier to
k after Onyx application.ysm r
ear a
terstcation, often with lethal consequences.12 There is a signif-
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and aneurysm rupture. This has led to the recommendation
that type IA endoleaks be repaired when identified. Al-
though endovascular repair of such endoleaks can be ac-
complished in 90% of cases, conversion to open repair may
still be required.13
Endovascular therapy was felt to be the only reasonable
treatment option for our patient, given her limited physio-
logic reserve and clear wishes to avoid open surgery. The
type IA endoleak was identified with angiography and the
flow channel selected with a microcatheter. The absence of
any outflow from within the aneurysm sac (ie, lumbar
branch or inferior mesenteric artery) was noted.
Onyx, which has been approved by the U.S. Food and
Drug Administration for the embolization of arteriovenous
malformations in the brain, was selected to embolize the
perigraft sac and flow channel due to several unique char-
acteristics that facilitate precise delivery. The technique of
endoleak embolization is similar to that for treatment of
brain arteriovenous malformations and thus guided by the
principle of complete seal and elimination of the nidus (leak
channel).14 If this is not done completely, the endoleak
might persist and continued pressurization of the aneurysm
sac could lead to its rupture.
Other options for embolization include coils, plugs, or
glues (N-butyl cyanoacrylate), but Onyx has several advan-
tages that were ideal for this situation.15,16 Unlike glues, it
is resistant to adhering to its delivery catheter. This allows
for slow and deliberate delivery without concern for injury
to the target lesion upon catheter removal. Precise delivery
also minimizes the possibility of misapplication or distal
embolization. In addition, its texture is well suited for
occupying spaces and conforming to irregular surfaces.
Disadvantages of Onyx include the 20-minute prepara-
tion time, potential for vasospasm, high cost, and the
Fig 3. Tantalum (inert metal) powder imparts radiopacity to
Onyx and is responsible for the imaging artifact on the computed
tomography image.transient patient experience of foul breath after use. Unin-tended placement or distal embolization can result in dev-
astating end-organ ischemia. Tantalum powder, which pro-
vides radiopacity for accurate delivery under fluoroscopy,
causes CT artifact (Fig 3). This has the potential to com-
plicate surveillance CT accuracy.
Although the use of Onyx in the management of type II
endoleaks is well described, this technique represents a new
therapeutic option for patients considered nonsurgical can-
didates or who are unwilling to accept surgical options in
the treatment of type IA endoleaks. Acceptable type IA
characteristics include a long, narrow nidus and absence of
an outflow vessel; therefore, this technique is not advocated
for all type IA endoleaks. The durability of this technique
remains unknown. The effect of perigraft embolization
with Onyx on pressure transmission into the sac has not
been studied. Patient follow-up remains mandatory for this
setting. Well-designed studies involving Onyx should take
place to compare outcomes after embolization therapy in
the treatment of endoleaks according to international re-
porting standards.
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